Ellevest, Inc. Neurocrine Biosciences Inc Transaction History

Ellevest, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 04, 2023	BUY	$94.11 - $123.02 $3,858 - $5,043	41 Added 51.25%	121 $12,000
Q4 2022 Feb 03, 2023	BUY	$106.72 - $127.06 $2,347 - $2,795	22 Added 37.93%	80 $9,000
Q3 2022 Nov 02, 2022	BUY	$92.03 - $107.81 $2,760 - $3,234	30 Added 107.14%	58 $6,000
Q2 2022 Jul 18, 2022	BUY	$75.79 - $100.07 $227 - $300	3 Added 12.0%	28 $3,000
Q1 2022 Apr 19, 2022	BUY	$72.45 - $94.81 $579 - $758	8 Added 47.06%	25 $2,000
Q4 2021 Jan 24, 2022	SELL	$79.65 - $106.22 $1,672 - $2,230	-21 Reduced 55.26%	17 $1,000
Q3 2021 Oct 19, 2021	BUY	$86.18 - $99.03 $3,274 - $3,763	38 New	38 $4,000
Q4 2020 Feb 04, 2021	SELL	$86.91 - $108.33 $1,564 - $1,949	-18 Closed	0 $0
Q1 2020 Apr 13, 2020	BUY	$75.11 - $113.76 $826 - $1,251	11 Added 157.14%	18 $2,000
Q3 2019 Oct 08, 2019	BUY	$83.82 - $101.5 $586 - $710	7 New	7 $1,000

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Ellevest, Inc., based on Form 13F filings with the SEC.

Stay updated on Ellevest, Inc. with notifications on news.